Epigenetic Ageing and Breast Cancer Risk: A Systematic Review

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2024-11-11 DOI:10.1002/cam4.70355

Emily McLennan, Danmeng Lily Li, Melissa C. Southey, Pierre-Antoine Dugué

{"title":"Epigenetic Ageing and Breast Cancer Risk: A Systematic Review","authors":"Emily McLennan, Danmeng Lily Li, Melissa C. Southey, Pierre-Antoine Dugué","doi":"10.1002/cam4.70355","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Age is one of the strongest risk factors for breast cancer. Measures of biological age based on DNA methylation have gained popularity for their strong association with risk of many diseases, including cancer, which may help to identify high-risk subgroups for targeted prevention.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We carried out a systematic review of prospective studies that examined the association of methylation-based markers of ageing with risk of invasive breast cancer in healthy (breast cancer-free) women, published up to May 2023. The search of three databases (MEDLINE, EMBASE and Web of Science) identified 2913 individual abstracts eligible for screening. Risk of bias assessment was conducted using ROBINS-E.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Ten prospective studies met the eligibility criteria, and these were heterogeneous in design and findings. The most frequently assessed epigenetic ageing measures were Horvath's first-generation clock, <i>PhenoAge</i> and <i>GrimAge</i>. Four studies reported mainly positive associations, five null associations and one reported a negative association. These associations were generally weak and the results were not consistent across epigenetic ageing measures.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The summarised evidence is insufficient to support a role for current epigenetic ageing measures to stratify breast cancer risk.</p>\n </section>\n \n <section>\n \n <p><b>PROSPERO Registration:</b> This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023417559)</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"13 21","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555139/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70355","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Age is one of the strongest risk factors for breast cancer. Measures of biological age based on DNA methylation have gained popularity for their strong association with risk of many diseases, including cancer, which may help to identify high-risk subgroups for targeted prevention.

Methods

We carried out a systematic review of prospective studies that examined the association of methylation-based markers of ageing with risk of invasive breast cancer in healthy (breast cancer-free) women, published up to May 2023. The search of three databases (MEDLINE, EMBASE and Web of Science) identified 2913 individual abstracts eligible for screening. Risk of bias assessment was conducted using ROBINS-E.

Results

Ten prospective studies met the eligibility criteria, and these were heterogeneous in design and findings. The most frequently assessed epigenetic ageing measures were Horvath's first-generation clock, PhenoAge and GrimAge. Four studies reported mainly positive associations, five null associations and one reported a negative association. These associations were generally weak and the results were not consistent across epigenetic ageing measures.

Conclusion

The summarised evidence is insufficient to support a role for current epigenetic ageing measures to stratify breast cancer risk.

PROSPERO Registration: This systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023417559)

Abstract Image

查看原文本刊更多论文

表观遗传老化与乳腺癌风险：系统综述》（Epigenetic Ageing and Breast Cancer Risk: A Systematic Review）。

背景：年龄是乳腺癌最主要的风险因素之一。基于 DNA 甲基化的生物年龄测量方法因其与包括癌症在内的多种疾病的风险密切相关而备受青睐，这可能有助于识别高风险亚群以进行有针对性的预防：我们对截至 2023 年 5 月发表的前瞻性研究进行了系统回顾，这些研究考察了基于甲基化的老化标志物与健康（未患乳腺癌）女性患侵袭性乳腺癌风险之间的关联。通过对三个数据库（MEDLINE、EMBASE 和 Web of Science）的检索，发现了 2913 篇符合筛选条件的摘要。使用 ROBINS-E 对偏倚风险进行了评估：结果：10 项前瞻性研究符合资格标准，这些研究的设计和研究结果各不相同。最常评估的表观遗传老化指标是 Horvath 的第一代时钟、PhenoAge 和 GrimAge。四项研究主要报告了正相关，五项报告了负相关，一项报告了负相关。这些关联性普遍较弱，而且不同的表观遗传老化测量结果也不一致：总结的证据不足以支持目前的表观遗传老化测量方法在乳腺癌风险分层中的作用。PROSPERO 注册：本系统综述已在《国际系统综述前瞻性注册》（PROSPERO：CRD42023417559）中注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.